Economic Report on the Pharmaceutical Industry in the First Half of 2024 Released

The report reveals that the industrial added value of large-scale pharmaceutical companies grew by 1.2% year-over-year. However, operating revenue and profit decreased by 1.4% and 1.2%, respectively, with growth significantly lagging behind the national industrial average.

pharmaceutical packaging

Biopharmaceuticals: Revenue rebounded, recovering from the impact of COVID-19 vaccine-related fluctuations.

Chemical APIs (Active Pharmaceutical Ingredients) and Formulations: Although revenue slightly declined, profits rose against the trend.

Traditional Chinese Medicine (TCM) Decoction Pieces: This was the only sub-sector to achieve simultaneous growth in both revenue and profit.

Chinese Patent Medicines and Healthcare Materials: These sub-sectors are facing dual challenges with declining revenue and profit.

Industry Challenges and Opportunities

The pharmaceutical industry is navigating downward pressure on drug prices, export growth, and rapid expansion of innovative products. As a result, the pharmaceutical packaging industry must adapt to these changes, focusing on high-quality and innovative packaging solutions to enhance competitiveness.

Xinfuda's Contribution to Sustainable Development

Xinfuda, committed to innovation and upgrading in pharmaceutical packaging, has introduced cutting-edge solutions such as child-resistant packaging, COP vials, and eye drop bottles, supporting the industry’s sustainable growth.

Amid the wave of transformation in the pharmaceutical sector, we leverage technological advantages and market insight to continuously optimize product structures and production processes. With a comprehensive quality management system, complete certifications, and environmental management accreditation, we are dedicated to practicing the concept of "Green Manufacturing." At Xinfuda, we lead with technology and safeguard health with responsibility!